Analyst Coverage
Diamond Equity Research
IMU: Q3 FY2024 Update, Intellectual Property Milestones, and Meaningful Clinical Trial Advancements Anticipated in 2H 2024
Roth Capital Partners
IMU: General Quarterly Business Update, 2H24 To Be Rich In Clinical Data
Bell Potter
Imugene Core Assets Progressing Nicely
Diamond Equity Research
IMU: Strategic Sale of North Carolina Facility and Clinical Trial Expansions Advancing
Roth Capital Partners
IMU: Sells CGMP Facility That Manufactures Azer-cel, MAST Trial Making Progress
Roth Capital Partners
Clinical Progress With onCARlytics And VAXINIA In Solid Tumors
Diamond Equity Research
Q2 FY2024 Clinical Milestones, Collaborations, and Financial Results Update
Diamond Equity Research
VAXINIA’s Releases Early Positive Data, PD1-Vaxx and Azer-cel Advancing Through Clinical Pipeline
Roth Capital Partners